Revolutionary Treatment Methods Linked to the Microbiome by Mbiomics
In the realm of medical innovation, several companies are making significant strides in developing complex microbiome-based therapies, particularly for immune-related and neurodegenerative diseases. While many of these companies focus on gastrointestinal and immune system disorders more broadly, one startup, mbiomics, is setting itself apart with its groundbreaking TechBio platform.
Based in Munich, mbiomics is a trailblazer in the field, differentiating itself through its emphasis on advanced computational and omics technology. The company's TechBio platform is designed to address these complex diseases at a systems biology level, contrasting with other firms' focus on defined bacterial consortia or single indication therapies.
The AI-powered design tools of mbiomics develop Live Biotherapeutic Products (LBPs) with functional precision. This precision is made possible by the platform's ability to integrate deep multi-omics data, including genomics, transcriptomics, metabolomics, and proteomics of the microbiome and host. The platform also utilizes AI-driven computational modeling to unravel complex host-microbiome interactions.
This approach allows mbiomics to design personalized or precision microbiome therapies based on patient-specific profiles, rather than broad consortia. The company's technological lead is based on three key competencies: proprietary analytics, co-culturing technology, and AI-powered design tools.
The founders of mbiomics, Johannes B. Woehrstein and Heinrich Grabmayr, are physicists and experienced biotech entrepreneurs. Johannes B. Woehrstein serves as the CEO and Co-Founder of mbiomics. In one year, the company plans to enter clinical trials with a pilot product in cancer therapy.
mbiomics offers an end-to-end platform for designing and scaling complex microbiome consortia. The company's co-culturing technology enables scalable production of these complex microbial consortia, which is crucial for the development and commercialization of novel therapeutic modalities.
The mission of mbiomics is to fundamentally transform the treatment of immune-related and neurodegenerative diseases. To achieve this, the company is working at maximum speed while simultaneously laying a solid foundation. Munich, with its proximity to excellent research, dense life science community, and access to talent and funding programs, is an ideal location for mbiomics.
In five years, mbiomics envisions itself as a champion and pioneer for microbiome-based therapies, with clinical projects in several diverse disease areas, including immuno-oncology, neurodegenerative, inflammatory, and autoimmune diseases. The company is seeking specialized investors in deep tech and life sciences who have the staying power this industry requires.
mbiomics' proprietary analytics precisely map and target multistrain ecosystems, offering a promising future for the treatment of complex diseases. As the company enters clinical trials and continues to make strides in the field, it represents a paradigm shift in pharmaceutical development, paving the way for a new era in medical innovation.
- The startup, mbiomics, situated in Munich, differentiates itself from other companies in the medical innovation field by developing complex microbiome-based therapies using its TechBio platform, which integrates advanced computational and omics technology.
- Mbiomics is distinct in its approach to complex diseases, focusing on addressing them at a systems biology level rather than designing defined bacterial consortia or single indication therapies.
- With its AI-powered design tools and co-culturing technology, mbiomics aims to design personalized or precision microbiome therapies, paving the way for a paradigm shift in pharmaceutical development and potentially revolutionizing the treatment of immune-related and neurodegenerative diseases.
